SHOX Deficiency and Associated Growth Disorders

The SHOX gene encodes a homeodomain transcription factor essential for normal skeletal development, particularly in the growth plate of long bones. Haploinsufficiency of SHOX—where one functional copy of the gene fails to sustain adequate protein levels—underlies a spectrum of growth disorders, ranging from idiopathic short stature to Léri-Weill dyschondrosteosis and, in homozygous cases, the more severe Langer mesomelic dysplasia. Phenotypic variability reflects not only the nature of coding mutations but also copy-number variations affecting distant enhancers and non-coding regulatory elements. Disruption of SHOX expression alters chondrocyte proliferation and differentiation, leading to disproportionate limb shortening and, in some cases, deformities of the wrist. The clinical burden of SHOX deficiency extends globally, with implications for genetic diagnosis, counselling and tailored therapies. Growth hormone treatment can increase final height when initiated early, yet response varies according to genotype, age and modifier factors. Advances in cellular and animal models have shed light on mechanisms of retinoic acid modulation, enhancer architecture and alternative splicing in SHOX regulation. Together, these insights offer a foundation for precision medicine approaches to improve outcomes for individuals affected by SHOX-related growth disorders.

Research from Nature Portfolio

Recent studies have delineated the cis-regulatory landscape of the SHOX locus by mapping conserved non-coding elements (CNEs) upstream and downstream of the gene. Functional assays in human cells and in vivo models reveal that multiple enhancers, some lying more than one megabase away, form a complex three-dimensional domain that orchestrates tissue-specific SHOX expression during limb development. In parallel, a limb-specific enhancer located downstream of the coding sequence has been identified through transgenic reporter analyses; pathogenic deletions of this element abolish enhancer activity in the developing zeugopod, providing a mechanistic explanation for mesomelic shortening in affected individuals. These findings underscore the importance of both proximal and distal regulatory modules in fine-tuning SHOX dosage and demonstrate how structural variants in non-coding DNA contribute to the phenotypic spectrum of SHOX deficiency.

SHOX Deficiency and Associated Growth Disorders publication trend

The graph below shows the total number of articles in shox deficiency and associated growth disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Haploinsufficiency: A genetic state in which a single functional copy of a gene does not produce enough gene product to preserve normal function.

Enhancer: A DNA sequence that increases the transcription of a target gene by serving as a binding site for transcription factors.

Conserved non-coding element (CNE): A segment of non-protein-coding DNA sequence preserved across species that can regulate gene expression.

Homeobox gene: A gene containing a homeobox domain encoding a transcription factor that directs cell differentiation and development.

Mesomelic dysplasia: A skeletal disorder characterised by disproportionate shortening of the middle segments of the limbs.

References

1. Monogenic causes of familial short stature. Frontiers in Endocrinology (2024).
2. Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency. EMBO Molecular Medicine (2016).
3. Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial. Hormone Research in Paediatrics (2016).
4. The Short Stature Homeodomain Protein SHOX Induces Cellular Growth Arrest and Apoptosis and Is Expressed in Human Growth Plate Chondrocytes*. Journal of Biological Chemistry (2004).
5. Profiling of conserved non-coding elements upstream of SHOX and functional characterisation of the SHOX cis-regulatory landscape. Scientific Reports (2015).
6. Identification of a limb enhancer that is removed by pathogenic deletions downstream of the SHOX gene. Scientific Reports (2018).
7. Alternative Splicing and Nonsense-Mediated RNA Decay Contribute to the Regulation of SHOX Expression. PLOS ONE (2011).
8. Variants in the 5′UTR reduce SHOX expression and contribute to SHOX haploinsufficiency. European Journal of Human Genetics (2020).